US Corporate Board Director Changes SEC Filings — June 05, 2026
This batch of 50 SEC filings reveals a significant wave of board and C-suite changes across US-listed companies, with notable patterns in shareholder dissent and executive departures. The most critical development is the concentrated resignation of Jordan Krugman from five Invesco-sponsored trusts, signaling a potential broader governance shift within the sponsor's management. Several annual meetings show elevated shareholder opposition, with NovoCure's equity plan passing by a razor-thin 0.6% margin and Claros Mortgage Trust receiving 33.6% 'against' votes on say-on-pay, indicating growing investor activism. The data reveals a trend of orderly CFO transitions, with companies like CaliberCos and Longeveron promoting internal candidates, while Aditxt's immediate loss of its General Counsel and Audit Committee Chair creates a governance vacuum. Key insider activity includes DBV Technologies granting CEO Daniel Tassé 4.06 million PSUs tied to FDA approval milestones, and Trio Petroleum awarding CEO Robin Ross a 50% salary increase plus 1.5 million shares. The period-over-period comparisons are limited in these board-focused filings, but the forward-looking data provides a clear catalyst calendar centered on August 2026 effective dates and regulatory milestones.